USPTO serial 87193653
CYTLIMIC
Reviewed by CopyMark Law Group
Reg. 5899961Status 710
- Filing date
- Status date
- Registration date
- Nov 5, 2019
- Examiner
- KAPLAN, VALERIE ELIZABETH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with CYTLIMIC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Minato-ku, Tokyo, JP
TOKYO, JP
Minato-ku, Tokyo, JP
Minato-ku, Tokyo, JP
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh Ann Lindquist
Leigh Ann Lindquist SUGHRUE MION, PLLC2000 PENNSYLVANIA AVE., NW Suite 9000WASHINGTON, DC 20006United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | bioactive peptides for scientific and medical research; chemicals for use in the manufacture of pharmaceuticals and pharmaceutical products; higher fatty acids for use in the field of scientific research, reagents and pharmaceuticals; chemical test paper; unprocessed plastics in the nature of plastics in primary form; medical protein for scientific and medical research purposes | SECTION 8 - CANCELLED | — |
| 005 | clinical medical reagents; pharmaceutical preparations for immunopotentiation and immunostimulation; synthetic peptides for pharmaceutical purposes; pharmaceutical preparations for immunity adjustment; anti-cancer agent containing medical peptides; vaccines to treat cancer containing medical peptides; antitumor drugs containing medical peptides; vaccines to tumor containing medical peptides; antitumor medicine containing medical peptides; medicine which help the active component of the vaccine act on living organism and improve immunity; medical peptide for the treatment of cancer; medical protein arrays for medical diagnosis purposes; medicine, namely, medicine that stabilizes the active ingredient of vaccines, in particular peptides and proteins; medicine that enhance the effectiveness of the active ingredient of a peptide or protein which is an active ingredient of vaccine; medical peptide and protein to be used in the immunotherapy and vaccine therapy to induce and activate the cells involved in antibody and immune response; anti-allergic agent containing medical peptides; medical peptide to be used in the vaccine therapy; medicine, namely, medical adjuvant of the immune adjuvant and enhancing agent which enhances immunity; mineral oil for medical purpose; pharmaceutical preparations for fluid therapies; pharmaceutical preparations and pharmaceutical preparation kits for assessing treatment effect and progress of treatment; pharmaceutical preparations and pharmaceutical preparation kits to identify hereditary risk factors; pharmaceutical preparations for the molecular arrangement diagnosis of biological substances, namely, extracts or analyte and nucleic acid, protein, polypeptide antibodies from organism; antibiotic preparations; anti-viral agents; chemotherapeutics; reagents for clinical medical reagents for use in diagnosing, treating or testing cancer; diagnostic reagents for use in diagnosing, treating or testing cancer; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; greases for medical purposes; gauze for dressings; empty capsules sold empty for pharmaceuticals; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; antiseptic liquid bandages; semen for artificial insemination; chemical reagents and chemical reagent kits for medical or veterinary purposes, namely, for providing effective genome therapy and identification of protein; chemical reagents and chemical reagent kits for medical or veterinary purposes, namely, for assessing therapeutic effect or progress of treatment; chemical reagent and chemical reagent kits for medical or veterinary purposes, namely, for identification of the inheritable risk factors; chemical reagents for the molecular arrangement diagnosis of biological substances, in particular, extracts or analyte of nucleic acid, protein, and polypeptide antibodies from organism | SECTION 8 - CANCELLED | — |
| 035 | business administration and office work, namely, supporting preparation of documents, paperwork used when representing application and performing other official procedure relating to clinical trial of pharmaceutical products in a medical institution; business administration relating to clinical trial of pharmaceutical products in a medical institution; business services, namely, medical business management analysis and business consultancy; business management analysis and business consultancy; business services, namely, medical business management information; information services relating to medical office administration; office functions, namely, filing, in particular documents or magnetic tape relating to clinical trial; business administration for others, namely, providing business assistance to others in the operation of data processing apparatus namely, computers, typewriters, and other similar office machines relating to clinical trial; advertising services; publicity services; promoting the goods and services of others through the administration of sales and promotional incentive schemes, namely, incentive award programs involving trading stamps; marketing research; providing information concerning commercial sales; import-export agencies; document reproduction; regulatory submission management, namely, assisting others in preparing and filing applications for approval of pharmaceuticals; business intermediary services relating to the matching of pharmaceutical companies with medical institutions conducting clinical trials of pharmaceutical products and other medical institutions | SECTION 8 - CANCELLED | — |
| 042 | conducting clinical trials for others; conducting clinical trials for pharmaceutical products; providing information about the results of clinical trials for pharmaceutical products; medical laboratory services; scientific research in the field of clinical conducting clinical trials for others; conducting clinical trials for pharmaceutical products; providing information about the results of clinical trials for pharmaceutical products; medical laboratory services; scientific research in the field of clinical trial of pharmaceutical products; providing information relating to clinical trial of pharmaceutical products; scientific research in the field of genomes, life science and pharmaceutical preparations; providing advice, explanation and information relating to scientific research in the field of genomes, life science and pharmaceutical preparations; scientific research, namely, testing, research and establishing a method of treatment in the field of method of treatment based on expression of gene and protein, and, based on activation of gene and protein; scientific research, namely, research, test and inspection in the field of therapeutic reagent for antibodies, antisense drugs, peptide, protein and gene; consulting and research of product development in the field of biomedicine, genetics and pharmacodynamics; test and development of product development in the field of biomedicine, genetics and pharmacodynamics; development, testing, inspection and advice regarding the development, testing, and inspection of preparations and other pharmaceutical preparations in the field of biomedicine, life science, including genes, and biology; testing, inspection and research of in the field of pharmaceuticals, cosmetics and foodstuffs; providing information in the field of testing, inspection and research in the field of pharmaceuticals; providing temporary use of non-downloadable software for data information processing in the field of pharmaceuticals; providing temporary use of non-downloadable software for data information processing; designing of machines, apparatus, instruments or systems composed of such machines, apparatus and instruments; computer software design, computer programming, or maintenance of computer software technological advice relating to installation of software on computers, automobiles and industrial machines; testing of and research on machines, apparatus and instruments for pharmaceutical products; rental of computers; rental of laboratory apparatus and instruments | SECTION 8 - CANCELLED | — |
| 044 | providing medical information relating to medical practice, medical services, nursing care, health and healthcare; consultancy and counselling relating to medical practice in the nature of the provision of medical services, medical services, nursing care, health and healthcare; medical services; providing medical information; physical examination; dentistry; preparation and dispensing of medications; dietary and nutritional guidance; rental of medical apparatus and instruments; information services relating to medical assistance, namely, information about home health aides | SECTION 8 - CANCELLED | — |
| 045 | licensing of technology, namely, pharmaceutical production technology; licensing of research and development, namely, licensing of intellectual; legal consultancy relating to industrial property rights; consultancy relating to intellectual property management, in particular on licensing of software for management of intellectual property; providing legal information on industrial property rights; licensing of industrial property rights; granting of licenses to others for the use of industrial property rights; legal services regarding the management of industrial property rights; intellectual property consultancy services for universities and research institutions; licensing of intellectual property; legal consultancy relating to the licensing of intellectual property; agencies for copyright licensing; legal services relating to social insurance claims | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NIPPON DENKI KABUSHIKI KAISHA
- Other trademarks owned by CYTLIMIC INC.
- Other trademarks owned by NIPPON DENKI KABUSHIKI KAISHA
- Other trademarks owned by NIPPON DENKI KABUSHIKI KAISHA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named CYTLIMIC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 15, 2026 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Dec 9, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Dec 9, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 9, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 9, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 9, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 9, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 9, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 5, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Dec 9, 2020 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 5, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 20, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 20, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 31, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 18, 2019 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Jul 18, 2019 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jun 22, 2019 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Jun 20, 2019 | APET | ASSIGNED TO PETITION STAFF | — |
| Jun 17, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 30, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 28, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 28, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 28, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 28, 2019 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Nov 29, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 27, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 27, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 27, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 9, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 7, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 7, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 7, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 28, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 3, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 3, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 13, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 31, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 18, 2017 | ALIE | ASSIGNED TO LIE | — |
| Aug 7, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 7, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 7, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 7, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 7, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 28, 2017 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jul 25, 2017 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jul 7, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 6, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 6, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 6, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 6, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 24, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 24, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 24, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 24, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 27, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 26, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 26, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 28, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 24, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 20, 2016 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Oct 11, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 8, 2016 | NWAP | NEW APPLICATION ENTERED | — |